Formoterol
Generic Name: Formoterol Fumarate
Brand Names: Foradil, Perforomist
Formoterol is a long-acting beta-agonist (LABA) used for maintenance treatment of asthma and COPD.
Drug Class
Long-Acting Beta-2 Adrenergic Agonist (LABA)
Pregnancy
Category C. Animal studies at very high doses showed some adverse fetal effects. No adequate human studies. Use during pregnancy only if the potential benefit justifies the potential risk. Uncontrolled asthma itself poses risks to the pregnancy.
Available Forms
Inhalation solution for nebulization (Perforomist) 20 mcg/2 mL vial, Dry powder inhaler (Foradil Aerolizer) 12 mcg/capsule
What It's Used For
Dosage Quick Reference
These are general dosage guidelines. Your doctor will determine the appropriate dose for your specific situation.
| Condition | Starting Dose | Maintenance Dose |
|---|---|---|
| Asthma (must be with ICS; ages 5+) | 12 mcg inhaled twice daily (Foradil) | 12 mcg inhaled twice daily (max 24 mcg/day) |
| COPD maintenance | 12 mcg inhaled twice daily (Foradil) or 20 mcg nebulized twice daily (Perforomist) | Same as starting dose; max 40 mcg/day for nebulization |
| Exercise-induced bronchospasm prevention | 12 mcg inhaled 15 minutes before exercise | Occasional use only; do not use if already on twice-daily formoterol |
Side Effects
Common Side Effects:
- Tremor
- Headache
- Dizziness
- Insomnia
- Nausea
- Dry mouth
- Muscle cramps
- Palpitations
- Upper respiratory infection
Serious Side Effects:
- Asthma-related death (without ICS)
- Paradoxical bronchospasm
- Cardiovascular effects (tachycardia, hypertension, arrhythmias)
- Hypokalemia
- Hyperglycemia
- Hypersensitivity reactions
Drug Interactions
- Non-selective beta-blockers (propranolol, nadolol): May block the bronchodilatory effect of formoterol and precipitate bronchospasm. Use cardioselective beta-blockers cautiously if needed.
- QT-prolonging drugs (sotalol, haloperidol, erythromycin): Formoterol may prolong the QT interval. Additive risk with other QT-prolonging medications.
- Diuretics (furosemide, hydrochlorothiazide): Beta-agonists may worsen diuretic-induced hypokalemia, increasing risk of cardiac arrhythmias. Monitor potassium levels.
- MAO inhibitors and tricyclic antidepressants: Potentiate cardiovascular effects (increased heart rate and blood pressure). Use extreme caution.
- Other LABAs (salmeterol, indacaterol): Do not use two LABAs simultaneously. Increased cardiovascular risk without additional bronchodilation benefit.
Additional Information
Formoterol is a long-acting beta-2 adrenergic agonist (LABA) bronchodilator used in the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). This medication provides rapid-onset, long-duration bronchodilation and is used in combination with inhaled corticosteroids for asthma management.
Mechanism of Action
Formoterol is a selective beta-2 adrenergic receptor agonist that binds to beta-2 receptors on airway smooth muscle cells. This binding activates adenylate cyclase, increasing intracellular cyclic AMP (cAMP) levels, which leads to relaxation of bronchial smooth muscle and bronchodilation. Formoterol has a unique pharmacological profile: it has rapid onset of action (within 1-3 minutes) similar to short-acting beta-agonists, yet also has a long duration of action (12 hours) characteristic of LABAs. This is due to its moderate lipophilicity, allowing both direct receptor binding and membrane partitioning with gradual release.
Available Formulations
Formoterol fumarate is available as a dry powder for inhalation in single-dose capsules (12 mcg) used with a specific inhaler device, and as a solution for nebulization. It is also available in fixed-dose combination inhalers with budesonide (for asthma and COPD), with mometasone (for asthma), and with aclidinium (for COPD). The formulation dictates the specific inhalation device used.
Medical Uses
Formoterol is FDA-approved for maintenance treatment of asthma in patients 5 years and older (only in combination with an inhaled corticosteroid), maintenance treatment of bronchoconstriction in COPD including chronic bronchitis and emphysema, and prevention of exercise-induced bronchospasm in patients 5 years and older. For asthma, LABAs should only be used in combination with an inhaled corticosteroid—never as monotherapy.
Dosing Guidelines
For asthma maintenance (with ICS), typical dosing is 12 mcg twice daily via DPI. For COPD maintenance, 12 mcg twice daily is standard. For prevention of exercise-induced bronchospasm, 12 mcg 15 minutes before exercise; additional doses should not be used for 12 hours. Maximum recommended dose is 24 mcg twice daily for asthma/COPD. When using fixed-dose combinations, follow the specific product labeling. Formoterol should not be used for acute symptom relief.
Important Safety Information
Formoterol carries a boxed warning stating that LABAs increase the risk of asthma-related death and should only be used for asthma in combination with an inhaled corticosteroid. Once asthma is well-controlled, step down therapy if possible. LABAs should not be used for acute symptoms; a rescue inhaler (SABA) should be available. Paradoxical bronchospasm may occur. Cardiovascular effects (tachycardia, hypertension, arrhythmias) may occur, particularly at higher doses. Hypokalemia and hyperglycemia are possible.
Drug Interactions
Beta-blockers may diminish the bronchodilatory effects of formoterol; selective beta-1 blockers may be used with caution when necessary. MAO inhibitors and tricyclic antidepressants may potentiate cardiovascular effects. QT-prolonging medications may increase the risk of arrhythmias. Diuretics may potentiate hypokalemia. Xanthine derivatives (theophylline), steroids, and other sympathomimetics may potentiate adverse effects.
Special Populations
There are no adequate studies in pregnant women. Beta-agonists may interfere with uterine contractility during labor. Use during pregnancy only if clearly needed. Formoterol is excreted in rat milk; caution is advised during breastfeeding. Safety and efficacy have been established in pediatric patients 5 years and older for asthma. Elderly patients may be more sensitive to cardiovascular effects; no specific dose adjustment is recommended. No dose adjustment is needed for renal or hepatic impairment based on available data, though caution is advised in severe disease.
Frequently Asked Questions
Questions to Ask Your Doctor
Consider discussing these topics at your next appointment:
- ✓Am I also on an inhaled corticosteroid, since formoterol should not be used alone for asthma?
- ✓Should I switch to a combination inhaler that includes both a steroid and formoterol?
- ✓Is twice-daily dosing of formoterol adequate, or should I consider a once-daily LABA?
- ✓Are my potassium levels being monitored since I am also on a diuretic?
Related Health Conditions
This medication is commonly used to treat or manage the following conditions:
Asthma
Asthma, a chronic lung disease, causes airway inflammation and narrowing, resulting in wheezing, coughing, and shortness of breath, triggered by allergens, irritants, infections, or stress.
Chronic Obstructive Pulmonary Disease (COPD)
COPD, a progressive lung disease causing irreversible airflow limitation, encompassing emphysema and chronic bronchitis, is primarily driven by irritant exposure like smoking, leading to shortness of breath and chronic cough.
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Related Medications
Other medications in the same category
Related Articles
Questions About This Medication?
Talk to your doctor or pharmacist about whether Formoterol is right for you.
Contact UsCall: (727) 820-7800